<SEC-DOCUMENT>0001558370-23-001975.txt : 20230224
<SEC-HEADER>0001558370-23-001975.hdr.sgml : 20230224
<ACCEPTANCE-DATETIME>20230224092618
ACCESSION NUMBER:		0001558370-23-001975
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		15
CONFORMED PERIOD OF REPORT:	20230224
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20230224
DATE AS OF CHANGE:		20230224

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Protalix BioTherapeutics, Inc.
		CENTRAL INDEX KEY:			0001006281
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				650643773
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-33357
		FILM NUMBER:		23662764

	BUSINESS ADDRESS:	
		STREET 1:		2 UNIVERSITY PLAZA
		STREET 2:		SUITE 100
		CITY:			HACKENSACK
		STATE:			NJ
		ZIP:			07601
		BUSINESS PHONE:		201-696-9345

	MAIL ADDRESS:	
		STREET 1:		2 UNIVERSITY PLAZA
		STREET 2:		SUITE 100
		CITY:			HACKENSACK
		STATE:			NJ
		ZIP:			07601

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ORTHODONTIX INC
		DATE OF NAME CHANGE:	19980422

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	EMBASSY ACQUISITION CORP
		DATE OF NAME CHANGE:	19960124
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>plx-20230224x8k.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='UTF-8'?>

      <!-- iXBRL document created with: Toppan Merrill Bridge iXBRL 10.2.0.4 -->
      <!-- Based on: iXBRL 1.1 -->
      <!-- Created on: 2/24/2023 12:59:23 PM -->
      <!-- iXBRL Library version: 1.0.8405.27969 -->
      <!-- iXBRL Service Job ID: 559b6506-db69-44cc-acea-540164ef94ed -->

  <html xmlns:dei="http://xbrl.sec.gov/dei/2021" xmlns="http://www.w3.org/1999/xhtml" xmlns:plx="http://protalix.com/20230224" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrli="http://www.xbrl.org/2003/instance"><head><meta http-equiv="content-type" content="text/html" /><title></title></head><body><div style="margin-top:30pt;"></div><div style="display:none;"><ix:header><ix:hidden><ix:nonNumeric contextRef="Duration_2_24_2023_To_2_24_2023_Mk-MnhXAlUGd_sPA2XXGFA" name="dei:EntityCentralIndexKey" id="Tc_RUJtyXMM_k6J8lEEC48Gpw_2_1">0001006281</ix:nonNumeric><ix:nonNumeric contextRef="Duration_2_24_2023_To_2_24_2023_Mk-MnhXAlUGd_sPA2XXGFA" name="dei:AmendmentFlag" id="Tc_doQFR-HdwEO5AiUwkzbMqA_3_1">false</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:href="plx-20230224.xsd" xlink:type="simple"></link:schemaRef></ix:references><ix:resources><xbrli:context id="Duration_2_24_2023_To_2_24_2023_Mk-MnhXAlUGd_sPA2XXGFA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-02-24</xbrli:startDate><xbrli:endDate>2023-02-24</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;min-height:13.8pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1pt;padding-bottom:1pt;padding-top:1pt;text-align:center;border-bottom:1.0pt solid #000000;border-top:3.0pt solid #000000;margin:0pt;"><span style="font-size:1pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:3pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_0e9ca0c2_ebd9_4bd2_825b_93ebacf24761"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">UNITED STATES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 4pt 0pt;"><b style="font-weight:bold;">Washington, D.C. 20549</b></p><div style="font-family:'Times New Roman','Times','serif';font-size:12.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">FORM&#160;</b><ix:nonNumeric contextRef="Duration_2_24_2023_To_2_24_2023_Mk-MnhXAlUGd_sPA2XXGFA" name="dei:DocumentType" id="Narr_tn1B81XvgUCYnpZOqbc4uA"><b style="font-weight:bold;">8-K</b></ix:nonNumeric></p><div style="font-family:'Times New Roman','Times','serif';font-size:12.0pt;margin-bottom:4pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">CURRENT REPORT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Pursuant to Section&#160;13 or 15(d)&#160;of</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">the Securities Exchange Act of 1934</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 4pt 0pt;"><b style="font-weight:bold;">Date of Report (Date of Earliest Event Reported): </b><ix:nonNumeric contextRef="Duration_2_24_2023_To_2_24_2023_Mk-MnhXAlUGd_sPA2XXGFA" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate" id="Narr_PxNH7Tb-H0i_5knqUWLPdw"><b style="font-weight:bold;">February&#160;24, 2023</b></ix:nonNumeric></p><div style="font-family:'Times New Roman','Times','serif';font-size:12.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:14pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_2_24_2023_To_2_24_2023_Mk-MnhXAlUGd_sPA2XXGFA" name="dei:EntityRegistrantName" id="Narr_U0RyX185eEaly1qXloddmQ"><b style="font-weight:bold;">Protalix BioTherapeutics,&#160;Inc.</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Exact name of registrant as specified in its charter)</b></p><div style="font-family:'Times New Roman','Times','serif';font-size:12.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_db44e2d3_a4d8_4690_a9da_b28605fc200d"></a><a id="Tc_UB1k-9cZKEWBFRBCkdXXIQ_2_0"></a><a id="Tc_Vm5EsKqA2UaG_YtC9tunhA_2_2"></a><a id="Tc_Rqyy8MtcD0Ccg1JPnbZWXg_2_4"></a><a id="Tc_gk-WEpWlnE24Wo24s1kvmA_6_0"></a><a id="Tc_ehUvfiY7FUaZTO0OV09HWw_7_0"></a><a id="Tc_k9CATQ80UEq33CgC1PxB2w_7_4"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:34.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:25.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:34.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:34.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_2_24_2023_To_2_24_2023_Mk-MnhXAlUGd_sPA2XXGFA" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="Tc_bAnGkqAak0mIy3VoW-sJfA_1_0"><b style="font-weight:bold;">Delaware</b></ix:nonNumeric></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:25.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_2_24_2023_To_2_24_2023_Mk-MnhXAlUGd_sPA2XXGFA" name="dei:EntityFileNumber" id="Tc_OptunCP73EefSJlJKEbhLw_1_2"><b style="font-weight:bold;">001-33357</b></ix:nonNumeric></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:34.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_2_24_2023_To_2_24_2023_Mk-MnhXAlUGd_sPA2XXGFA" name="dei:EntityTaxIdentificationNumber" id="Tc_m5BGk_MgS0KFbtwZ-9QzyA_1_4"><b style="font-weight:bold;">65-0643773</b></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:bottom;width:34.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(State or other jurisdiction</b><br /><b style="font-weight:bold;">of incorporation)</b></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:25.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Commission File Number)</b></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:34.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(IRS Employer</b><b style="font-weight:bold;"><br /></b><b style="font-weight:bold;">Identification No.)</b></p></td></tr><tr><td style="vertical-align:bottom;width:34.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:25.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:34.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:34.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_2_24_2023_To_2_24_2023_Mk-MnhXAlUGd_sPA2XXGFA" name="dei:EntityAddressAddressLine1" id="Tc_FEpow5i2GUqhH5yh12u8bg_4_0"><b style="font-weight:bold;">2 University Plaza</b></ix:nonNumeric></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:25.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:34.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:34.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_2_24_2023_To_2_24_2023_Mk-MnhXAlUGd_sPA2XXGFA" name="dei:EntityAddressAddressLine2" id="Tc_Ru-qYdWpeESvjnqx0sg-fw_5_0"><b style="font-weight:bold;">Suite 100</b></ix:nonNumeric></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:25.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:34.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:34.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_2_24_2023_To_2_24_2023_Mk-MnhXAlUGd_sPA2XXGFA" name="dei:EntityAddressCityOrTown" id="Narr__lTCyHiWQUWG5B7MmP75KQ"><b style="font-weight:bold;">Hackensack</b></ix:nonNumeric><b style="font-weight:bold;">, </b><ix:nonNumeric contextRef="Duration_2_24_2023_To_2_24_2023_Mk-MnhXAlUGd_sPA2XXGFA" name="dei:EntityAddressStateOrProvince" id="Narr_wFEMuD0dt0eQGhhksvUd0Q"><b style="font-weight:bold;">NJ</b></ix:nonNumeric></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:25.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:34.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_2_24_2023_To_2_24_2023_Mk-MnhXAlUGd_sPA2XXGFA" name="dei:EntityAddressPostalZipCode" id="Tc_1VxSqvdYbUux4NZPjLfFqw_6_4"><b style="font-weight:bold;">07601</b></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:bottom;width:34.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Address of principal executive offices)</b></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:25.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:34.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Zip Code)</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;">&#160;<b style="font-weight:bold;">Registrant&#8217;s telephone number, including area code </b><ix:nonNumeric contextRef="Duration_2_24_2023_To_2_24_2023_Mk-MnhXAlUGd_sPA2XXGFA" name="dei:CityAreaCode" id="Narr_EkEqaMxEH0mC-a3f6q9Tqg"><b style="font-weight:bold;">201</b></ix:nonNumeric><b style="font-weight:bold;">-</b><ix:nonNumeric contextRef="Duration_2_24_2023_To_2_24_2023_Mk-MnhXAlUGd_sPA2XXGFA" name="dei:LocalPhoneNumber" id="Narr_PGp7xreobUaNH7VqQ-mmBw"><b style="font-weight:bold;">696-9345</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Former name or former address, if changed since last report.)</b></p><div style="font-family:'Times New Roman','Times','serif';font-size:12.0pt;margin-bottom:10pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Check the appropriate box below if the Form&#160;8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (<i style="font-style:italic;">see</i> General Instruction A.2. below):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><ix:nonNumeric contextRef="Duration_2_24_2023_To_2_24_2023_Mk-MnhXAlUGd_sPA2XXGFA" format="ixt-sec:boolballotbox" name="dei:WrittenCommunications" id="Narr_ZIe_ZacRV0WyXbmsW_ti-A"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></ix:nonNumeric>&#160;&#160;&#160;&#160;Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><ix:nonNumeric contextRef="Duration_2_24_2023_To_2_24_2023_Mk-MnhXAlUGd_sPA2XXGFA" format="ixt-sec:boolballotbox" name="dei:SolicitingMaterial" id="Narr_lqbE-gf1Q0mpPaoEUcnRBQ"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></ix:nonNumeric>&#160;&#160;&#160;&#160;Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><ix:nonNumeric contextRef="Duration_2_24_2023_To_2_24_2023_Mk-MnhXAlUGd_sPA2XXGFA" format="ixt-sec:boolballotbox" name="dei:PreCommencementTenderOffer" id="Narr_CZQpJgSzV0ezbilK-Jclng"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></ix:nonNumeric>&#160;&#160;&#160;&#160;Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_2_24_2023_To_2_24_2023_Mk-MnhXAlUGd_sPA2XXGFA" format="ixt-sec:boolballotbox" name="dei:PreCommencementIssuerTenderOffer" id="Narr_KWvRV7Cv9EyQwEWK07yUvw"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></ix:nonNumeric>&#160;&#160;&#160;&#160;Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Securities registered pursuant to Section&#160;12(b)&#160;of the Act:</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_e77e804a_d223_4729_927d_c6bf13fbe4e3"></a><a id="Tc_uSV1uNID3UKVjXw9--BZQA_1_0"></a><a id="Tc_1QGqTfBJC0uoKcE-89yypA_1_1"></a><a id="Tc_gTpvLZQBn0CelwmcyCwbTQ_1_2"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:40%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:19.99%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:39.99%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:40%;border-bottom:1.0pt solid #000000;border-left:1.0pt solid #000000;border-right:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt 4.9pt 0pt 4.9pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Title of each class</p></td><td style="vertical-align:bottom;width:19.99%;border-bottom:1.0pt solid #000000;border-right:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt 4.9pt 0pt 4.9pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Trading Symbol(s)</p></td><td style="vertical-align:bottom;width:39.99%;border-bottom:1.0pt solid #000000;border-right:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt 4.9pt 0pt 4.9pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Name of each exchange on which registered</p></td></tr><tr><td style="vertical-align:top;width:40%;border-bottom:1.0pt solid #000000;border-left:1.0pt solid #000000;border-right:1.0pt solid #000000;margin:0pt;padding:0pt 4.9pt 0pt 4.9pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_2_24_2023_To_2_24_2023_Mk-MnhXAlUGd_sPA2XXGFA" name="dei:Security12bTitle" id="Tc_tIASKy3THki0DMdtrP6DEg_2_0">Common stock, $0.001 par value</ix:nonNumeric></p></td><td style="vertical-align:top;width:19.99%;border-bottom:1.0pt solid #000000;border-right:1.0pt solid #000000;margin:0pt;padding:0pt 4.9pt 0pt 4.9pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_2_24_2023_To_2_24_2023_Mk-MnhXAlUGd_sPA2XXGFA" name="dei:TradingSymbol" id="Tc_CJm5ZPIpD0q0diTTiBHhbw_2_1">PLX</ix:nonNumeric></p></td><td style="vertical-align:top;width:39.99%;border-bottom:1.0pt solid #000000;border-right:1.0pt solid #000000;margin:0pt;padding:0pt 4.9pt 0pt 4.9pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_2_24_2023_To_2_24_2023_Mk-MnhXAlUGd_sPA2XXGFA" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="Tc_G0hSrmbCTEe3RjgciNvsGQ_2_2">NYSE American</ix:nonNumeric></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule&#160;405 of the Securities Act of 1933 (17 CFR &#167;230.405) or Rule&#160;12b-2 of the Securities Exchange Act of 1934 (17 CFR &#167;240.12b-2).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 10pt 0pt;">Emerging growth company <ix:nonNumeric contextRef="Duration_2_24_2023_To_2_24_2023_Mk-MnhXAlUGd_sPA2XXGFA" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany" id="Narr_3uBONuy2TUWa2CUMjlCQBQ"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a)&#160;of the Exchange Act. <span style="font-family:Times New Roman;">&#9723;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:3pt;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1pt;padding-bottom:1pt;padding-top:1pt;border-bottom:3.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;"><span style="font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:72pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Item&#160;8.01</b></span>Other Events</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="color:#212529;">On February&#160;24, 2023, the Company, together with its commercialization partner, Chiesi Global Rare Diseases, a business unit of the Chiesi Group, announced today that the European Medicines Agency&#8217;s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending marketing authorization for PRX-102 (pegunigalsidase alfa), the first and only pegylated enzyme for the treatment of adult patients with Fabry disease. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:72pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Item&#160;9.01</b></span>Financial Statements and Exhibits</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:12.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:0.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:86.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:12.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Exhibit No.</p></td><td style="vertical-align:bottom;width:0.93%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:86.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Description</p></td></tr><tr><td style="vertical-align:top;width:12.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">99.1</p></td><td style="vertical-align:bottom;width:0.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="plx-20230224xex99d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Press Release dated February&#160;24, 2023</span></a></p></td></tr><tr><td style="vertical-align:top;width:12.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">104</p></td><td style="vertical-align:bottom;width:0.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cover Page Interactive Data File (embedded within the Inline XBRL document)</p></td></tr><tr><td style="vertical-align:top;width:12.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">SIGNATURES</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:56.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:3.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:6.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:33.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:56.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date: February&#160;24, 2023</p></td><td colspan="3" style="vertical-align:top;width:43.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:56.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:3.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:6.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:33.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:56.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:3.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td colspan="2" style="vertical-align:top;width:40.02%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Dror Bashan</p></td></tr><tr><td style="vertical-align:top;width:56.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:3.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:6.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name:</p></td><td style="vertical-align:top;width:33.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Dror Bashan</p></td></tr><tr><td style="vertical-align:top;width:56.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:3.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:6.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title:</p></td><td style="vertical-align:top;width:33.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">President and Chief Executive Officer</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:avoid;width:79.3%;border:0;"></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>plx-20230224xex99d1.htm
<DESCRIPTION>EX-99.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.14.0.96--><!--Created on: 2/24/2023 12:59:22 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;min-height:36pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><b style="font-weight:bold;">Exhibit 99.1</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;table-layout:fixed;width:99.89%;"><tr style="height:1pt;"><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><img src="plx-20230224xex99d1001.jpg" alt="Graphic" style="display:inline-block;height:38.5pt;left:0%;padding-bottom:0.5pt;position:relative;top:0pt;width:128pt;"></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><img src="plx-20230224xex99d1002.jpg" alt="Graphic" style="display:inline-block;height:48.75pt;left:0%;padding-bottom:0.75pt;position:relative;top:0pt;width:128.65pt;"></p></td></tr></table></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-family:'Verdana Pro Light';font-size:16pt;font-weight:bold;">Chiesi Global Rare Diseases and Protalix BioTherapeutics Receive Positive CHMP Opinion for Pegunigalsidase Alfa for Treatment of Fabry Disease</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-family:'Verdana Pro Light';font-weight:bold;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><i style="font-family:'Verdana Pro Light';font-style:italic;">- European Commission decision anticipated in beginning of May 2023 -</i></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="font-family:'Verdana Pro Light';font-style:italic;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt;"><b style="font-family:'Verdana Pro Light';font-weight:bold;">PARMA/BOSTON and CARMIEL, Israel, February 24, 2023</b><font style="font-family:'Verdana Pro Light';"> &#8211; Chiesi Global Rare Diseases, a business unit of the Chiesi Group established to deliver innovative therapies and solutions for people affected by rare diseases, and Protalix BioTherapeutics, Inc. (NYSE&#160;American:PLX) (TASE:PLX), a biopharmaceutical company, announced today that the European Medicines Agency&#8217;s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending marketing authorization for PRX-102 (pegunigalsidase alfa), the first and only pegylated enzyme for the treatment of adult patients with Fabry disease.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="font-family:'Verdana Pro Light';line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="font-family:'Verdana Pro Light';">&#8220;</font><i style="font-family:'Verdana Pro Light';font-style:italic;">Chiesi and our partners at Protalix are deeply committed to people living with Fabry disease and their families, many of whom experience unmet medical needs</i><font style="font-family:'Verdana Pro Light';">,&#8221; said </font><b style="font-family:'Verdana Pro Light';font-weight:bold;">Giacomo Chiesi, Head of Chiesi Global Rare Diseases</b><font style="font-family:'Verdana Pro Light';">. &#8220;</font><i style="font-family:'Verdana Pro Light';font-style:italic;">Our deepest gratitude to all the individuals with Fabry disease who have participated in clinical trials. Thanks to them, PRX-102 has been extensively studied during the clinical development program, providing the data for the CHMP&#8217;s evaluation and positive opinion regarding a positive benefit-risk profile for PRX-102. We look forward to advancing towards approval and launch in Europe and will continue our mission to deliver this potential new treatment option to people living with Fabry disease around the world</i><font style="font-family:'Verdana Pro Light';">.&#8221;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="font-family:'Verdana Pro Light';line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="font-family:'Verdana Pro Light';">PRX-102 is a novel recombinant human &#945;</font><font style="font-family:'Cambria Math';">-</font><font style="font-family:'Verdana Pro Light';">Galactosidase</font><font style="font-family:'Cambria Math';">-</font><font style="font-family:'Verdana Pro Light';">A (&#945;-Gal-A) enzyme being investigated as an enzyme replacement therapy (ERT) for the treatment of Fabry disease. The positive CHMP opinion was based on a marketing authorization application (MAA) that includes positive data from a comprehensive set of preclinical, clinical and manufacturing studies evaluating PRX-102. The clinical development program includes the completed Phase&#160;3 BALANCE, BRIDGE, and BRIGHT clinical trials, the Phase&#160;1/2 clinical trial, and ongoing related extension studies that combined represent more than 400 years of exposure to PRX-102. PRX-102 has been studied in more than 140 patients, consisting of both ERT-na&#239;ve and ERT-experienced patients, and includes a head-to-head trial versus agalsidase beta.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="font-family:'Verdana Pro Light';line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="font-family:'Verdana Pro Light';">&#8220;</font><i style="font-family:'Verdana Pro Light';font-style:italic;">We are pleased to be another step closer to approval in Europe with the CHMP&#8217;s positive opinion recommending marketing authorization for PRX-102 for adult patients with Fabry Disease</i><font style="font-family:'Verdana Pro Light';">,&#8221; said </font><b style="font-family:'Verdana Pro Light';font-weight:bold;">Dror Bashan, Protalix&#8217;s President and Chief Executive Officer</b><font style="font-family:'Verdana Pro Light';">. &#8220;</font><i style="font-family:'Verdana Pro Light';font-style:italic;">We believe that this recommendation further recognizes the strength of the positive dataset from our robust clinical trial program and underscores the potential for PRX-102 to provide a new </i></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="display:inline-block;width:166.5pt;"></font><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt;"><i style="font-family:'Verdana Pro Light';font-style:italic;">treatment option for patients with Fabry disease. Data from our clinical program indicates that PRX-102 has the potential to be a long lasting therapy with a favorable tolerability and immunogenicity profile. Together with Chiesi, we remain committed to bringing PRX-102 to market and working to potentially improve the quality of life of patients with Fabry disease. We thank the study personnel for their dedication and look forward to the final European Commission decision on the MAA</i><font style="font-family:'Verdana Pro Light';">.&#8221;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="font-family:'Verdana Pro Light';line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="font-family:'Verdana Pro Light';">The CHMP opinion is now referred for final action to the European Commission (EC). A final EC decision on the MAA is expected in the beginning of May 2023.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="font-family:'Verdana Pro Light';line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt;"><b style="font-family:'Verdana Pro Light';font-weight:bold;">About Fabry Disease</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="font-family:'Verdana Pro Light';">Fabry disease is an X-linked inherited disease that results from deficient activity of the lysosomal &#945;-Galactosidase</font><font style="font-family:'Cambria Math';">-</font><font style="font-family:'Verdana Pro Light';">A enzyme resulting in progressive accumulation of abnormal deposits of a fatty substance called globotriaosylceramide (Gb</font><sub style="font-family:'Verdana Pro Light';font-size:8.25pt;vertical-align:sub;">3</sub><font style="font-family:'Verdana Pro Light';">) in the lysosomes throughout a person&#8217;s body. Fabry disease occurs in one person per 40,000 to 60,000. Fabry patients inherit a deficiency of the &#945;</font><font style="font-family:'Cambria Math';">-</font><font style="font-family:'Verdana Pro Light';">Galactosidase</font><font style="font-family:'Cambria Math';">-</font><font style="font-family:'Verdana Pro Light';">A enzyme, which is normally responsible for the breakdown of Gb</font><sub style="font-family:'Verdana Pro Light';font-size:8.25pt;vertical-align:sub;">3</sub><font style="font-family:'Verdana Pro Light';">. The abnormal storage of Gb</font><sub style="font-family:'Verdana Pro Light';font-size:8.25pt;vertical-align:sub;">3</sub><font style="font-family:'Verdana Pro Light';"> increases with time and, accordingly, Gb</font><sub style="font-family:'Verdana Pro Light';font-size:8.25pt;vertical-align:sub;">3</sub><font style="font-family:'Verdana Pro Light';"> accumulates, primarily in the blood vessel and tissues. The ultimate consequences of Gb</font><sub style="font-family:'Verdana Pro Light';font-size:8.25pt;vertical-align:sub;">3</sub><font style="font-family:'Verdana Pro Light';"> deposition range from episodes of pain and impaired peripheral sensation to end-organ failure &#8211; particularly of the kidneys, but also of the heart and the cerebrovascular system.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="font-family:'Verdana Pro Light';line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt;"><b style="font-family:'Verdana Pro Light';font-weight:bold;">About PRX</b><b style="font-family:'Cambria Math';font-weight:bold;">&#8209;</b><b style="font-family:'Verdana Pro Light';font-weight:bold;">102</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="font-family:'Verdana Pro Light';">PRX</font><font style="font-family:'Cambria Math';">&#8209;</font><font style="font-family:'Verdana Pro Light';">102 (pegunigalsidase alfa) is an investigational, novel, PEGylated enzyme replacement therapy (ERT) under development to treat unmet medical needs for Fabry patients, such as progressive kidney decline. PRX-102 is a plant cell culture-expressed, and chemically modified stabilized version of the recombinant &#945;</font><font style="font-family:'Cambria Math';">&#8209;</font><font style="font-family:'Verdana Pro Light';">Galactosidase</font><font style="font-family:'Cambria Math';">&#8209;</font><font style="font-family:'Verdana Pro Light';">A enzyme. Protein sub-units are covalently bound via chemical cross-linking using short PEG moieties, resulting in a molecule with unique pharmacokinetic parameters. In clinical studies, PRX</font><font style="font-family:'Cambria Math';">&#8209;</font><font style="font-family:'Verdana Pro Light';">102 has been observed to have a circulatory half-life of approximately 80 hours.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="font-family:'Verdana Pro Light';line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt;"><b style="font-family:'Verdana Pro Light';font-weight:bold;">About Chiesi Global Rare Diseases</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="font-family:'Verdana Pro Light';">Chiesi Global Rare Diseases is a business unit of the Chiesi Group established to deliver innovative therapies and solutions for people affected by rare diseases. As a family business, Chiesi Group strives to create a world where it is common to have a therapy for all diseases and acts as a force for good, for society and the planet. The goal of the Global Rare Diseases unit is to ensure equal access so as many people as possible can experience their most fulfilling life. The unit collaborates with the rare disease community around the globe to bring voice to underserved people in the health care system. For more information visit </font><font style="font-family:'Verdana Pro Light';">www.chiesirarediseases.com</font><font style="font-family:'Verdana Pro Light';">.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="font-family:'Verdana Pro Light';line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt;"><b style="font-family:'Verdana Pro Light';font-weight:bold;">About Chiesi Group</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="font-family:'Verdana Pro Light';font-size:11pt;">Chiesi is an international, research-focused biopharmaceuticals group that develops and markets innovative therapeutic solutions</font><font style="color:#212121;font-family:'Verdana Pro Light';font-size:10.5pt;"> in respiratory health, rare diseases, and specialty care. </font><font style="color:#212121;font-family:'Verdana Pro Light';font-size:10.5pt;">The company&#8217;s</font><font style="color:#212121;font-family:'Verdana Pro Light';font-size:10.5pt;"> mission is to improve people&#8217;s quality of life and act responsibly towards both the community and the environment. </font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="color:#212121;font-family:'Verdana Pro Light';font-size:10.5pt;font-weight:bold;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:justify;margin:0pt 0pt 8pt 0pt;"><font style="color:#212121;font-family:'Verdana Pro Light';font-size:10.5pt;">By changing its legal status to a Benefit Corporation in Italy, the US, and France, Chiesi&#8217;s commitment to create shared value for society as a whole is legally binding and central to company-wide decision-making.&#160;As a certified B Corp since 2019, we&#8217;re part of a global community of businesses that meet high standards of social and environmental impact. The company aims at becoming net-zero by 2035. </font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="color:#212121;font-family:'Verdana Pro Light';font-size:10.5pt;">With over 85 years of experience, Chiesi is headquartered in Parma (Italy), operates in 30 countries, and counts more than 6,000 employees. The Group&#8217;s research and development centre in Parma works alongside 6 other important R&amp;D hubs in France, the US, Canada, China, the UK, and Sweden.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="color:#212121;font-family:'Verdana Pro Light';font-size:10.5pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="color:#212121;font-family:'Verdana Pro Light';font-size:10.5pt;">For further information please visit </font><font style="font-family:'Verdana Pro Light';font-size:10.5pt;">www.chiesi.com</font><font style="color:#0563c1;font-family:'Verdana Pro Light';font-size:10.5pt;text-decoration-line:none;">.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="color:#212121;font-family:'Verdana Pro Light';font-size:10.5pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt;"><b style="font-family:'Verdana Pro Light';font-weight:bold;">About Protalix BioTherapeutics, Inc.</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="font-family:'Verdana Pro Light';">Protalix is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx</font><sup style="font-family:'Verdana Pro Light';font-size:8.25pt;vertical-align:top;">&#174;</sup><font style="font-family:'Verdana Pro Light';">. Protalix was the first company to gain U.S.&#160;Food and Drug Administration (FDA) approval of a protein produced through plant cell-based in suspension expression system. Protalix&#8217;s unique expression system represents a new method for developing recombinant proteins in an industrial-scale manner.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="font-family:'Verdana Pro Light';line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="font-family:'Verdana Pro Light';">Protalix&#8217;s first product manufactured by ProCellEx, taliglucerase alfa, was approved by the FDA in May 2012 and, subsequently, by the regulatory authorities of other countries. Protalix has licensed to Pfizer Inc. the worldwide development and commercialization rights for taliglucerase alfa, excluding Brazil, where Protalix retains full rights.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="font-family:'Verdana Pro Light';line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="font-family:'Verdana Pro Light';">Protalix&#8217;s development pipeline consists of proprietary versions of recombinant therapeutic proteins that target established pharmaceutical markets, including the following product candidates: pegunigalsidase alfa, a modified stabilized version of the recombinant human &#945;-Galactosidase-A protein for the treatment of Fabry disease; PRX</font><font style="font-family:'Cambria Math';">&#8209;</font><font style="font-family:'Verdana Pro Light';">115, a plant cell-expressed recombinant PEGylated uricase for the treatment of severe gout; PRX</font><font style="font-family:'Cambria Math';">&#8209;</font><font style="font-family:'Verdana Pro Light';">119, a plant cell-expressed long action DNase&#160;I for the treatment of NETs-related diseases; and others. Protalix has partnered with Chiesi Farmaceutici S.p.A., both in the United States and outside the United States, for the development and commercialization of pegunigalsidase alfa.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="font-family:'Verdana Pro Light';line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt;"><b style="font-family:'Verdana Pro Light';font-weight:bold;">Forward Looking Statements</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="font-family:'Verdana Pro Light';">To the extent that statements in this press release are not strictly historical, all such statements are forward-looking, and are made pursuant to the safe-harbor provisions of the Private Securities Litigation Reform Act of 1995. The terms &quot;expect,&quot; &quot;anticipate,&quot; &quot;believe,&quot; &quot;estimate,&quot; &quot;project,&quot; &quot;may,&quot; &quot;plan,&quot; &quot;will,&quot; &quot;would,&quot; &quot;should&quot; and &quot;intend,&quot; and other words or phrases of similar import are intended to identify forward-looking statements. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual future experience and results to differ materially from the statements made. These statements are based on our current beliefs and expectations as to such future outcomes. Drug discovery and development involve a high degree of risk and the final results of a clinical trial may be different than the preliminary findings for the clinical trial. Factors that might cause material differences include, among </font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="font-family:'Verdana Pro Light';">others: risks related to the timing, progress and likelihood of final approval by the European Medicines Agency&#160;(EMA) of the Marketing Authorization Application; the risk that the U.S.&#160;Food and Drug Administration (FDA) might not grant marketing approval for PRX-102 by the PDUFA date or at all, and other risks related to the timing, progress and likelihood of final approval by the FDA of the PRX-102 Biologics License Application (BLA); the risk that a marketing approval of PRX-102 by either the FDA or the EMA will be conditioned on significant limitations on its use; risks related to the commercial success of PRX-102, and of our other product and product candidates, if approved; the likelihood that the FDA, EMA or other applicable health regulatory authorities will approve an alternative dosing regimen; failure or delay in the commencement or completion of our preclinical studies and clinical trials, which may be caused by several factors, including: slower than expected rates of patient recruitment; unforeseen safety issues; determination of dosing issues; lack of effectiveness during clinical trials; inability to satisfactorily demonstrate non-inferiority to approved therapies; inability or unwillingness of medical investigators and institutional review boards to follow our clinical protocols; and inability to monitor patients adequately during or after treatment; delays in the approval or potential rejection of any applications we file with the FDA, EMA or other health regulatory authorities for our other product candidates, and other risks relating to the review process; risks associated with the novel coronavirus disease, or COVID&#8211;19, outbreak, which may adversely impact our business, preclinical studies and clinical trials; risks related to any transactions we may effect in the public or private equity markets to raise capital to finance future research and development activities, general and administrative expenses and working capital; the risk that the results of the clinical trials of our product candidates will not support the applicable claims of safety or efficacy, or that our product candidates will not have the desired effects or will be associated with undesirable side effects or other unexpected characteristics; risks related to our ability to maintain and manage our relationship with our collaborators, distributors or partners; risks related to the amount and sufficiency of our cash, cash equivalents and short-term deposits; risks relating to our ability to make scheduled payments of the principal of, to pay interest on or to refinance our outstanding notes or any other indebtedness; our dependence on performance by third party providers of services and supplies, including without limitation, clinical trial services; delays in our preparation and filing of applications for regulatory approval; the inherent risks and uncertainties in developing drug platforms and products of the type we are developing; the impact of development of competing therapies and/or technologies by other companies and institutions; potential product liability risks, and risks of securing adequate levels of product liability and other necessary insurance coverage; and other factors described in our filings with the U.S.&#160;Securities and Exchange Commission. The statements in this press release are valid only as of the date hereof and we disclaim any obligation to update this information, except as may be required by law.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="font-family:'Verdana Pro Light';line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt;"><b style="font-family:'Verdana Pro Light';font-weight:bold;">Chiesi Global Rare Diseases Media Contact</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="font-family:'Verdana Pro Light';">Adam Daley</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="font-family:'Verdana Pro Light';">Berry &amp; Company Public Relations</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="font-family:'Verdana Pro Light';">1-212-253-8881</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="font-family:'Verdana Pro Light';">adaley@berrypr.com</font><font style="font-family:'Verdana Pro Light';"> </font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="font-family:'Verdana Pro Light';line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt;"><b style="font-family:'Verdana Pro Light';font-weight:bold;">Protalix Investor Contact </b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="font-family:'Verdana Pro Light';">Chuck Padala, Managing Director</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="font-family:'Verdana Pro Light';">LifeSci Advisors</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="font-family:'Verdana Pro Light';">646-627-8390</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="font-family:'Verdana Pro Light';">chuck@lifesciadvisors.com</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="font-family:'Verdana Pro Light';line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt;"><b style="font-family:'Verdana Pro Light';font-weight:bold;">Source:</b><font style="font-family:'Verdana Pro Light';"> </font><b style="font-family:'Verdana Pro Light';font-weight:bold;">Chiesi Global Rare Diseases</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt;"><b style="font-family:'Verdana Pro Light';font-weight:bold;"> &#160;</b><b style="font-family:'Verdana Pro Light';font-weight:bold;">Protalix BioTherapeutics, Inc.</b><a name="_Hlk127296543"></a></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:avoid;width:76.47%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>plx-20230224xex99d1001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 plx-20230224xex99d1001.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1"  T *L# 2(  A$! Q$!_\0
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M@F]^R5;Q^,?C5\<?'FH#SM6&O-HELTG+6]M%G"#T!"Q_]\4 :=C^S7\4O%L
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M?Q;^)-AK2C9+X8FU>;^UDN/^> MA'O9\\# *GKG'- 'L?CG]HO1/"GPO\/\
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M+6[^(/@+_A&_#=S-' VM:=JJ:A%8L[!4^U*$1D0L0#(NY02,X'-=-\1?BO\
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M,#% ';A%!S@9]<4AB4G)Y-%% "3V\=S$T4J++&PPR. P/U!IT<:Q(J(H1%&
MJC  HHH  @!) Y/6@(%! XS110 *@4\<5&;2$W G,2>>!M$NT;@/3/6BB@"1
MD#')YHV\#KQ110!%%9P0&0Q0QQ&0Y<H@&X^_K7D7CQ0O[37PF Z#2M<_]!M:
M** /7H+."V+F&)(BYR_EJ%W'U..M2LH=2K %2,$'O110!';VT5I&(X(DAC'.
MR-0H_(47%K%=QF.:-)8SU210P/X&BB@!ZQJF-H P,# Z#TH$:KNP.&ZBBB@
M"!5P.![5%%900-(T4,<32'+E%"EC[XZT44 /EMXY]OF1K)M.1N4'!]>:>!@4
%44 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>plx-20230224xex99d1002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 plx-20230224xex99d1002.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" !B 0(# 2(  A$! Q$!_\0
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M WA;1+?PUX:TK2+6,0VNGVD5I%&&+!$C0(!D\G 7J:\)_P""@OCE?A_^R/\
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MK=_I$-RLFI6,44US;@',:2EQ&2<8Y\M^G]VO%[[XH?%/X9:QI-UX^T+PO?\
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M-OV9\S_;SGWH O>'_#5CI?PNTWP_HMP]QIMOH\5A97$A!9XE@"1L2 ,DJ >
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5&-(HU481%  _ 444D)$]%%%,9__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>5
<FILENAME>plx-20230224.xsd
<DESCRIPTION>EX-101.SCH
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  10.2.0.4 -->
<!--Based on XBRL 2.1-->
<!--Created on: 2/24/2023 12:59:26 PM-->
<!--Modified on: 2/24/2023 12:59:26 PM-->
<xsd:schema targetNamespace="http://protalix.com/20230224" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:dei="http://xbrl.sec.gov/dei/2021" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:srt-types="http://fasb.org/srt-types/2021-01-31" xmlns:us-roles="http://fasb.org/us-roles/2021-01-31" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:currency="http://xbrl.sec.gov/currency/2021" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:naics="http://xbrl.sec.gov/naics/2021" xmlns:srt-roles="http://fasb.org/srt-roles/2021-01-31" xmlns:country="http://xbrl.sec.gov/country/2021" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:exch="http://xbrl.sec.gov/exch/2021" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:sic="http://xbrl.sec.gov/sic/2021" xmlns:us-types="http://fasb.org/us-types/2021-01-31" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:stpr="http://xbrl.sec.gov/stpr/2021" xmlns:attributeFormDefault="unqualified" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:plx="http://protalix.com/20230224" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:deprecated="http://www.xbrl.org/2009/role/deprecated" xmlns:net="http://www.xbrl.org/2009/role/net">
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://protalix.com/role/DocumentDocumentAndEntityInformation" id="DocumentDocumentAndEntityInformation">
        <link:definition>00090 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:type="simple" xlink:href="plx-20230224_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="plx-20230224_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/dei/2021" schemaLocation="https://xbrl.sec.gov/dei/2021/dei-2021.xsd" />
  <xsd:element name="DocumentAndEntityInformationAbstract" id="plx_DocumentAndEntityInformationAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>6
<FILENAME>plx-20230224_lab.xml
<DESCRIPTION>EX-101.LAB
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  10.2.0.4 -->
<!--Based on XBRL 2.1-->
<!--Created on: 2/24/2023 12:59:26 PM-->
<!--Modified on: 2/24/2023 12:59:26 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink">
  <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:href="plx-20230224.xsd#plx_DocumentAndEntityInformationAbstract" xlink:label="plx_DocumentAndEntityInformationAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_DocumentAndEntityInformationAbstract" xlink:to="plx_DocumentAndEntityInformationAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_DocumentAndEntityInformationAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document and Entity Information [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Type</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Period End Date</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity File Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Registrant Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Incorporation, State or Country Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Tax Identification Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Address Line One</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Adress Line Two</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, State or Province</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, City or Town</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Postal Zip Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">City Area Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Local Phone Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Written Communications</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Soliciting Material</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Pre-commencement Tender Offer</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Pre-commencement Issuer Tender Offer</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Title of 12(b) Security</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Trading Symbol</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Security Exchange Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Emerging Growth Company</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Central Index Key</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amendment Flag</label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>7
<FILENAME>plx-20230224_pre.xml
<DESCRIPTION>EX-101.PRE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  10.2.0.4 -->
<!--Based on XBRL 2.1-->
<!--Created on: 2/24/2023 12:59:26 PM-->
<!--Modified on: 2/24/2023 12:59:26 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink">
  <roleRef xlink:type="simple" xlink:href="plx-20230224.xsd#DocumentDocumentAndEntityInformation" roleURI="http://protalix.com/role/DocumentDocumentAndEntityInformation" xmlns="http://www.xbrl.org/2003/linkbase" />
  <presentationLink xlink:role="http://protalix.com/role/DocumentDocumentAndEntityInformation" xlink:type="extended" xlink:title="00090 - Document - Document and Entity Information" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="plx-20230224.xsd#plx_DocumentAndEntityInformationAbstract" xlink:label="plx_DocumentAndEntityInformationAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType" xlink:label="dei_DocumentType_638128403669464774" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentType_638128403669464774" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate_638128403669464774" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentPeriodEndDate_638128403669464774" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber_638128403669464774" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityFileNumber_638128403669464774" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName_638128403669464774" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityRegistrantName_638128403669464774" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode_638128403669464774" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityIncorporationStateCountryCode_638128403669464774" order="5" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber_638128403669464774" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityTaxIdentificationNumber_638128403669464774" order="6" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1_638128403669464774" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityAddressAddressLine1_638128403669464774" order="7" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2_638128403669464774" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityAddressAddressLine2_638128403669464774" order="8" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince_638128403669464774" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityAddressStateOrProvince_638128403669464774" order="9" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown_638128403669464774" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityAddressCityOrTown_638128403669464774" order="10" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode_638128403669464774" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityAddressPostalZipCode_638128403669464774" order="11" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode_638128403669474800" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_DocumentAndEntityInformationAbstract" xlink:to="dei_CityAreaCode_638128403669474800" order="12" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber_638128403669474800" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_DocumentAndEntityInformationAbstract" xlink:to="dei_LocalPhoneNumber_638128403669474800" order="13" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications_638128403669474800" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_DocumentAndEntityInformationAbstract" xlink:to="dei_WrittenCommunications_638128403669474800" order="14" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial_638128403669474800" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_DocumentAndEntityInformationAbstract" xlink:to="dei_SolicitingMaterial_638128403669474800" order="15" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer_638128403669474800" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_DocumentAndEntityInformationAbstract" xlink:to="dei_PreCommencementTenderOffer_638128403669474800" order="16" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer_638128403669474800" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_DocumentAndEntityInformationAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer_638128403669474800" order="17" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle_638128403669474800" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_DocumentAndEntityInformationAbstract" xlink:to="dei_Security12bTitle_638128403669474800" order="18" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol_638128403669474800" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_DocumentAndEntityInformationAbstract" xlink:to="dei_TradingSymbol_638128403669474800" order="19" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName_638128403669474800" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_DocumentAndEntityInformationAbstract" xlink:to="dei_SecurityExchangeName_638128403669474800" order="20" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany_638128403669474800" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityEmergingGrowthCompany_638128403669474800" order="21" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey_638128403669474800" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityCentralIndexKey_638128403669474800" order="22" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag_638128403669484808" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_DocumentAndEntityInformationAbstract" xlink:to="dei_AmendmentFlag_638128403669484808" order="23" use="optional" />
  </presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139777734864304">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Feb. 24, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_DocumentAndEntityInformationAbstract', window );"><strong>Document and Entity Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Feb. 24,  2023<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-33357<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Protalix BioTherapeutics,&#160;Inc.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">65-0643773<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">2 University Plaza<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Adress Line Two</a></td>
<td class="text">Suite 100<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NJ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Hackensack<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">07601<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">201<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">696-9345<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common stock, $0.001 par value<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">PLX<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSEAMER<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001006281<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_DocumentAndEntityInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_DocumentAndEntityInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>plx-20230224x8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2021"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="plx-20230224.xsd" xlink:type="simple"/>
    <context id="Duration_2_24_2023_To_2_24_2023_Mk-MnhXAlUGd_sPA2XXGFA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
        </entity>
        <period>
            <startDate>2023-02-24</startDate>
            <endDate>2023-02-24</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey
      contextRef="Duration_2_24_2023_To_2_24_2023_Mk-MnhXAlUGd_sPA2XXGFA"
      id="Tc_RUJtyXMM_k6J8lEEC48Gpw_2_1">0001006281</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag
      contextRef="Duration_2_24_2023_To_2_24_2023_Mk-MnhXAlUGd_sPA2XXGFA"
      id="Tc_doQFR-HdwEO5AiUwkzbMqA_3_1">false</dei:AmendmentFlag>
    <dei:DocumentType
      contextRef="Duration_2_24_2023_To_2_24_2023_Mk-MnhXAlUGd_sPA2XXGFA"
      id="Narr_tn1B81XvgUCYnpZOqbc4uA">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="Duration_2_24_2023_To_2_24_2023_Mk-MnhXAlUGd_sPA2XXGFA"
      id="Narr_PxNH7Tb-H0i_5knqUWLPdw">2023-02-24</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName
      contextRef="Duration_2_24_2023_To_2_24_2023_Mk-MnhXAlUGd_sPA2XXGFA"
      id="Narr_U0RyX185eEaly1qXloddmQ">Protalix BioTherapeutics,&#160;Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="Duration_2_24_2023_To_2_24_2023_Mk-MnhXAlUGd_sPA2XXGFA"
      id="Tc_bAnGkqAak0mIy3VoW-sJfA_1_0">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="Duration_2_24_2023_To_2_24_2023_Mk-MnhXAlUGd_sPA2XXGFA"
      id="Tc_OptunCP73EefSJlJKEbhLw_1_2">001-33357</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber
      contextRef="Duration_2_24_2023_To_2_24_2023_Mk-MnhXAlUGd_sPA2XXGFA"
      id="Tc_m5BGk_MgS0KFbtwZ-9QzyA_1_4">65-0643773</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="Duration_2_24_2023_To_2_24_2023_Mk-MnhXAlUGd_sPA2XXGFA"
      id="Tc_FEpow5i2GUqhH5yh12u8bg_4_0">2 University Plaza</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="Duration_2_24_2023_To_2_24_2023_Mk-MnhXAlUGd_sPA2XXGFA"
      id="Tc_Ru-qYdWpeESvjnqx0sg-fw_5_0">Suite 100</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="Duration_2_24_2023_To_2_24_2023_Mk-MnhXAlUGd_sPA2XXGFA"
      id="Narr__lTCyHiWQUWG5B7MmP75KQ">Hackensack</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="Duration_2_24_2023_To_2_24_2023_Mk-MnhXAlUGd_sPA2XXGFA"
      id="Narr_wFEMuD0dt0eQGhhksvUd0Q">NJ</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="Duration_2_24_2023_To_2_24_2023_Mk-MnhXAlUGd_sPA2XXGFA"
      id="Tc_1VxSqvdYbUux4NZPjLfFqw_6_4">07601</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="Duration_2_24_2023_To_2_24_2023_Mk-MnhXAlUGd_sPA2XXGFA"
      id="Narr_EkEqaMxEH0mC-a3f6q9Tqg">201</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="Duration_2_24_2023_To_2_24_2023_Mk-MnhXAlUGd_sPA2XXGFA"
      id="Narr_PGp7xreobUaNH7VqQ-mmBw">696-9345</dei:LocalPhoneNumber>
    <dei:WrittenCommunications
      contextRef="Duration_2_24_2023_To_2_24_2023_Mk-MnhXAlUGd_sPA2XXGFA"
      id="Narr_ZIe_ZacRV0WyXbmsW_ti-A">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="Duration_2_24_2023_To_2_24_2023_Mk-MnhXAlUGd_sPA2XXGFA"
      id="Narr_lqbE-gf1Q0mpPaoEUcnRBQ">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="Duration_2_24_2023_To_2_24_2023_Mk-MnhXAlUGd_sPA2XXGFA"
      id="Narr_CZQpJgSzV0ezbilK-Jclng">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="Duration_2_24_2023_To_2_24_2023_Mk-MnhXAlUGd_sPA2XXGFA"
      id="Narr_KWvRV7Cv9EyQwEWK07yUvw">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle
      contextRef="Duration_2_24_2023_To_2_24_2023_Mk-MnhXAlUGd_sPA2XXGFA"
      id="Tc_tIASKy3THki0DMdtrP6DEg_2_0">Common stock, $0.001 par value</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="Duration_2_24_2023_To_2_24_2023_Mk-MnhXAlUGd_sPA2XXGFA"
      id="Tc_CJm5ZPIpD0q0diTTiBHhbw_2_1">PLX</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="Duration_2_24_2023_To_2_24_2023_Mk-MnhXAlUGd_sPA2XXGFA"
      id="Tc_G0hSrmbCTEe3RjgciNvsGQ_2_2">NYSEAMER</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany
      contextRef="Duration_2_24_2023_To_2_24_2023_Mk-MnhXAlUGd_sPA2XXGFA"
      id="Narr_3uBONuy2TUWa2CUMjlCQBQ">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>10
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MTG1X#SY['R73>RHY_U=3_ 102P,$%     @ 2$M85I>*NQS     $P(   L
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M;64O=&AE;64Q+GAM;%!+ 0(4 Q0    ( $A+6%8Z;6WE:@0  %<1   8
M          " @0T(  !X;"]W;W)K<VAE971S+W-H965T,2YX;6Q02P$"% ,4
M    " !(2UA6GZ ;\+$"  #B#   #0              @ &M#   >&PO<W1Y
M;&5S+GAM;%!+ 0(4 Q0    ( $A+6%:7BKL<P    !,"   +
M  "  8D/  !?<F5L<R\N<F5L<U!+ 0(4 Q0    ( $A+6%8<.&7J/P$  #P"
M   /              "  7(0  !X;"]W;W)K8F]O:RYX;6Q02P$"% ,4
M" !(2UA6)!Z;HJT   #X 0  &@              @ '>$0  >&PO7W)E;',O
M=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4    " !(2UA699!YDAD!  #/ P
M$P              @ '#$@  6T-O;G1E;G1?5'EP97-=+GAM;%!+!08
.."0 ) #X"   -%      !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.4</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>23</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="plx-20230224x8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00090 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://protalix.com/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="plx-20230224x8k.htm">plx-20230224x8k.htm</File>
    <File>plx-20230224.xsd</File>
    <File>plx-20230224_lab.xml</File>
    <File>plx-20230224_pre.xml</File>
    <File>plx-20230224xex99d1.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="23">http://xbrl.sec.gov/dei/2021</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>15
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "plx-20230224x8k.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2021": 23
   },
   "contextCount": 1,
   "dts": {
    "inline": {
     "local": [
      "plx-20230224x8k.htm"
     ]
    },
    "labelLink": {
     "local": [
      "plx-20230224_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "plx-20230224_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "plx-20230224.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.sec.gov/dei/2021/dei-2021.xsd"
     ]
    }
   },
   "elementCount": 24,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2021": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 23,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "plx",
   "nsuri": "http://protalix.com/20230224",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20230224x8k.htm",
      "contextRef": "Duration_2_24_2023_To_2_24_2023_Mk-MnhXAlUGd_sPA2XXGFA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "00090 - Document - Document and Entity Information",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://protalix.com/role/DocumentDocumentAndEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20230224x8k.htm",
      "contextRef": "Duration_2_24_2023_To_2_24_2023_Mk-MnhXAlUGd_sPA2XXGFA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Adress Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "plx_DocumentAndEntityInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document and Entity Information [Abstract]"
       }
      }
     },
     "localname": "DocumentAndEntityInformationAbstract",
     "nsuri": "http://protalix.com/20230224",
     "xbrltype": "stringItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r5": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>16
<FILENAME>0001558370-23-001975-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001558370-23-001975-xbrl.zip
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M:4G$/* :H=5PEM5[)IB9YWNU =(=7DAUJ^AN..^(B? N$TSO4#"]"P/3^Q_
MW' Y6-"JN4PN,5Y8C]%73 +SQ:I1?BET&H)J 2UH+X%14\EOA>GZ4E2-4#6H
M';'YP@9T0?9-14YY*7CNQM.2N9%= I2::M^*1VDM<93F5:/8HS'WH[_PK/3V
MWB"^%""U(;5,YI27@*6^X+<B,W4'85_5[;H\%MH,^08<"\T6 Z@+HI#;;K,4
M,FV)IV*5+'#2K2J*Y-,K46]"B?GK&8W$8II,@111Q79+J3*6>2I9B2$DCM5]
M2O,GPYPCTJ'3Z9QDGQ'%FK0FG<6<E493L&E%EA)77NNIV&6ND+>M +T^C7"
M.2;C9W$/P["ORZP560R=.90B;E=A*6XEA9[*VL82E&<%H/48DG C\<8E3PC)
MAR#9RVBD/9>6BBT&;W](!:!9:2F(!Q1\*I#"V@FVO"$UA\2]>C2?XGB.V%&
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M:L.]=?R>G'JGTMH.&]Z^;O;A'U!+ P04    " !(2UA6UH[(69(4   FF0
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M?Y26-Y8O[VJ_SCM']Z-V=FE^3,AE!?'3I<8B7K*YVC8%#-9M;" R)JK'9N3
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M6I@;=1U:NC8_Z/HP_%4LS8<_/7=@[/\_4$L#!!0    ( $A+6%9@++$O[AH
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M&WRUW0.ZEL >,EA-]*MI'$S8H_2QR(I4+41(8Y%]7#%LL"9I@&;,ECA/U'/
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M+3(P,C,P,C(T+GAS9%!+ 0(4 Q0    ( $A+6%;+$O_'F@4  .$^   4
M          "  >H#  !P;'@M,C R,S R,C1?;&%B+GAM;%!+ 0(4 Q0    (
M $A+6%;J_$+DE00  $(J   4              "  ;8)  !P;'@M,C R,S R
M,C1?<')E+GAM;%!+ 0(4 Q0    ( $A+6%;6CLA9DA0  ":9   3
M      "  7T.  !P;'@M,C R,S R,C1X.&LN:'1M4$L! A0#%     @ 2$M8
M5F LL2_N&@  98H  !<              ( !0",  '!L>"TR,#(S,#(R-'AE
?>#DY9#$N:'1M4$L%!@     %  4 2 $  &,^      $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
